Alcon
Stories
-
Alcon posts results of Phase 3 FID 123320 study
The study enrolled 284 participants and was completed with results first posted on ClinicalTrials.gov on November 10, 2026. It assessed the safety and efficacy of FID 123320 Ophthalmic Solution (Apraclonidine HCl 0.125%) versus vehicle for relieving ocular redness in pediatric and adult populations.
-
Alcon posts results of Phase 3 apraclonidine study for ocular redness
The study enrolled 159 participants and was completed on November 14, 2024. Results were first posted on ClinicalTrials.gov on November 10, 2026.